Xu Wu

This inventor holds 8 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Irm LLC, The General Hospital Corporation, Scripps Research Institute. Active years: 2007-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xu Wu. Retrieved from https://idiyas.com/inventor/xu-wu-83j36efi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 5)

% Patents Active = 50.0

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 10)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 53(Granted Patents)

Location History:

San Diego, CA (US) (2007 - 2013)
San Deigo, CA (US) (2013)
Lexington, MA (US) (2014 - 2020)

Company Filing History:

The General Hospital Corporation

patents

1 out of 1,208

Scripps Research Institute

patents

4. 1 out of 834,513

Other

patents

Years Active: 2007-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12187722 - Small molecule inhibitors of TEAD transcription factors (2025-01-07),

2. 10696642 - TEAD transcription factor autopalmitoylation inhibitors (2020-06-30),

3. 8722692 - Compounds and compositions as Syk kinase inhibitors (2014-05-13),

4. 8546370 - Compounds and compositions as kinase inhibitors (2013-10-01),

5. 8507471 - Biphenylcarboxamide derivatives as hedgehod pathway modulators (2013-08-13),

6. 8354526 - Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors (2013-01-15),

7. 8178563 - Compounds and compositions as hedgehog pathway modulators (2012-05-15),

8. 7273864 - Compositions and methods for inducing osteogenesis (2007-09-25),

Title: Xu Wu: Innovator in TEAD Transcription Factor Inhibition

Introduction

Xu Wu is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of biochemistry, particularly in the development of small molecule inhibitors targeting TEAD transcription factors. With a total of 8 patents, his work is pivotal in advancing therapeutic options for diseases such as cancer.

Latest Patents

Xu Wu's latest patents include innovative compounds that inhibit the activity of TEAD transcription factors. The first patent focuses on small molecule inhibitors that are useful in treating diseases related to TEAD activity, including cancer. The second patent also addresses TEAD transcription factor autopalmitoylation inhibitors, which similarly aim to provide therapeutic benefits against diseases associated with TEAD.

Career Highlights

Throughout his career, Xu Wu has worked with notable organizations, including Irm LLC and The General Hospital Corporation. His expertise in the field has allowed him to develop groundbreaking solutions that address critical health challenges.

Collaborations

Xu Wu has collaborated with esteemed colleagues such as Qiang Ding and Yahua Liu, contributing to a rich environment of innovation and research.

Conclusion

Xu Wu's contributions to the field of biochemistry, particularly through his patents on TEAD transcription factor inhibitors, highlight his role as a key innovator. His work continues to pave the way for advancements in the treatment of serious diseases.

Profile summary based on public USPTO records.